Literature DB >> 10909853

Giant axonal neuropathy locus refinement to a < 590 kb critical interval.

L Cavalier1, C BenHamida, R Amouri, S Belal, P Bomont, N Lagarde, L Gressin, D Callen, E Demir, H Topaloglu, P Landrieu, C Ioos, M B Hamida, M Koenig, F Hentati.   

Abstract

Giant axonal neuropathy (GAN) is a rare autosomal recessive neurodegenerative disorder, characterised clinically by the development of chronic distal polyneuropathy during childhood, mental retardation, kinky or curly hair, skeletal abnormalities and, ultrastructurally, by axons in the central and peripheral nervous systems distended by masses of tightly woven neurofilaments. We recently localised the GAN locus in 16q24.1 to a 5-cM interval between the D16S507 and D16S511 markers by homozygosity mapping in three consanguineous Tunisian families. We have now established a contig-based physical map of the region comprising YACs and BACs where we have placed four genes, ten ESTs, three STSs and two additional microsatellite markers, and where we have identified six new SSCP polymorphisms and six new microsatellite markers. Using these markers, we have refined the position of our previous flanking recombinants. We also identified a shared haplotype between two Tunisian families and a small region of homozygosity in a Turkish family with distant consanguinity, both suggesting the occurrence of historic recombinations and supporting the conclusions based on the phase-known recombinations. Taken together, these results allow us to establish a transcription map of the region, and to narrow down the GAN position to a < 590 kb critical interval, an important step toward the identification of the defective gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10909853     DOI: 10.1038/sj.ejhg.5200476

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  8 in total

1.  Giant axonal neuropathy: clinical and genetic study in six cases.

Authors:  E Demir; P Bomont; S Erdem; L Cavalier; M Demirci; G Kose; S Muftuoglu; A N Cakar; E Tan; S Aysun; M Topcu; P Guicheney; M Koenig; H Topaloglu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

2.  Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.

Authors:  Saleemulla Mahammad; S N Prasanna Murthy; Alessandro Didonna; Boris Grin; Eitan Israeli; Rodolphe Perrot; Pascale Bomont; Jean-Pierre Julien; Edward Kuczmarski; Puneet Opal; Robert D Goldman
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

Review 3.  A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer.

Authors:  James J Kang; Isabelle Y Liu; Marilene B Wang; Eri S Srivatsan
Journal:  Hum Genet       Date:  2016-03-29       Impact factor: 4.132

Review 4.  Neurofilaments: neurobiological foundations for biomarker applications.

Authors:  Arie R Gafson; Nicolas R Barthélemy; Pascale Bomont; Roxana O Carare; Heather D Durham; Jean-Pierre Julien; Jens Kuhle; David Leppert; Ralph A Nixon; Roy O Weller; Henrik Zetterberg; Paul M Matthews
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

5.  Genetics and genomic medicine in Tunisia.

Authors:  Houda Elloumi-Zghal; Habiba Chaabouni Bouhamed
Journal:  Mol Genet Genomic Med       Date:  2018-03       Impact factor: 2.183

6.  Genome-wide analyses of gene expression during mouse endochondral ossification.

Authors:  Claudine G James; Lee-Anne Stanton; Hanga Agoston; Veronica Ulici; T Michael Underhill; Frank Beier
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

7.  New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy.

Authors:  Henry Houlden; Mike Groves; Zosia Miedzybrodzka; Helen Roper; Tracey Willis; John Winer; Gaynor Cole; Mary M Reilly
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-06-19       Impact factor: 10.154

Review 8.  E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy.

Authors:  Léa Lescouzères; Pascale Bomont
Journal:  Front Physiol       Date:  2020-10-22       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.